ClinicalTrials.Veeva

Menu

99mTc-anti-TNF-alpha Scintigraphy in the Evaluation of Inflammatory Processes Activity

U

Universidade Federal do Rio de Janeiro

Status and phase

Unknown
Phase 2

Conditions

Arthritis
Psoriatic Arthritis

Treatments

Other: 99mTc-anti-TNF-alpha Scintigraphy

Study type

Interventional

Funder types

Other

Identifiers

NCT02134613
CONEP-711/2008

Details and patient eligibility

About

Rheumatoid and psoriatic arthritis patients benefit from anti-TNF-α therapy, once it is effective in reducing joint and skin manifestations in 60-70% of patients with inflammatory articular joint and skin diseases. Thus, identifying the presence and amount of TNF-α in the joint or skin in these patients may help in guiding the course of treatment more efficiently. The investigators research group has developed a novel approach to label anti-TNF-α with technetium-99m. Here the investigators compare the results obtained with scintigraphy and MRI in rheumatoid and psoriatic arthritis. The 99mTc-anti-TNF-α scintigraphy might recognize the molecule involved in the inflammatory process and provide crucial information to help physicians taking decisions about the drugs to be used based on biological evidence and which are cost-effective and appropriate for the treatment of choice. It allows direct identification of the monoclonal antibody anti-TNF-α in the articular joints and skin while it also ensures that the drug has reached its therapeutic target. It also allows correlation between the presence of the drug and clinical responses.

Enrollment

50 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Rheumatoid Arthritis (RA) patients must have 1 joint with edema.
  • Inflammatory lumbalgia
  • ankylosing spondylitis
  • Psoriatic arthritis with active disease and skin lesion

Exclusion criteria

  • Patients that do not return to scintigraphy
  • Pregnancy, Lactation, active infection, severe concomitant disease and medication allergy history

Trial design

Primary purpose

Diagnostic

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

50 participants in 1 patient group

anti-TNF-alpha scintigraphy
Experimental group
Description:
99mTc-anti-TNF-alpha Scintigraphy will be compared with MRI results, analysed and discussed by physicians who are in charge of the patients.
Treatment:
Other: 99mTc-anti-TNF-alpha Scintigraphy

Trial contacts and locations

1

Loading...

Central trial contact

Bianca Gutfilen, PhD; Sergio A Souza, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems